Efficacy and safety of intra-articular injection of dexamethasone palmitate in promoting ERAS after knee arthroscopy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200056488

Enrollment

Unknown

Registered

2022-02-06

Start date

2022-02-01

Completion date

Unknown

Last updated

2024-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases of knee arthroscopic surgery

Interventions

Control group (C):Intra-articular injection of saline

Group A:Intra-articular injection of 8mg dexamethasone palmitate

Group B:Intra-articular injection of 5mg dexamethasone

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The American Society of Anesthesiologists classified as grade I-II; 2. Regardless of gender; 3. Aged 18 to 75 years old; 4. Patients underwent knee arthroscopy; 5. The surgery mainly involved synovial debridement, free body removal and meniscinoplasty.

Exclusion criteria

Exclusion criteria: 1. History of perioperative drug allergy in the past; 2. Serious chronic diseases that affected normal postoperative recovery; 3. Other diseases that affected inflammatory indicators such as rheumatoid diseases or infections.

Design outcomes

Primary

Measure	Time frame
Visual analogue scale;Erythrocyte sedimentation rate;C-reactive protein;Il-6;	—

Secondary

Measure	Time frame
Incidence of postoperative nausea and vomiting;Swelling of knee joint;Adverse reaction;	—

Countries

China

Contacts

Public ContactZhou Ming

Zibo Central Hospital

18678187705@163.com+86 18678187705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026